AR043379A1 - Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k - Google Patents

Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k

Info

Publication number
AR043379A1
AR043379A1 ARP040100573A ARP040100573A AR043379A1 AR 043379 A1 AR043379 A1 AR 043379A1 AR P040100573 A ARP040100573 A AR P040100573A AR P040100573 A ARP040100573 A AR P040100573A AR 043379 A1 AR043379 A1 AR 043379A1
Authority
AR
Argentina
Prior art keywords
compound
maxi
pten
disease
useful
Prior art date
Application number
ARP040100573A
Other languages
English (en)
Inventor
Ki Whan Hong
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR043379A1 publication Critical patent/AR043379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Abridor de PTEN o un nuevo abridor de un canal K' activado por Ca2+ de gran conductancia (canal Maxi-K) que comprende como un ingrediente activo un compuesto de tetrazolilalcoxi-dihidrocarboestirilo de la fórmula (1), en donde R es cicloalquilo, A es un grupo alquileno inferior y el enlace entre las posiciones 3 y 4 del núcleo de carboestirilo significa un enlace simple o un enlace doble, o una sal del mismo, que es útil como un medicamento para la promoción de la supervivencia de las células normales, las células cerebrales, las células cardiacas y la piel, y además para inhibir la sepsis Gram-negativa y la migración celular y la invasión celular debido a la inhibición de PTEN y es útil además como un medicamento para el tratamiento del edema cerebral regional y deterioro motor neurológico, trastornos cognitivos, lesión cerebral traumática, enfermedad de Parkinson, epilepsia, migrana y enfermedad de Alzheimer, etc.. Composición farmacéutica que comprende dicho compuesto de la fórmula (1) y el uso del compuesto para prepararla.
ARP040100573A 2003-02-25 2004-02-24 Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k AR043379A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US44958903P 2003-02-26 2003-02-26

Publications (1)

Publication Number Publication Date
AR043379A1 true AR043379A1 (es) 2005-07-27

Family

ID=32930512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100573A AR043379A1 (es) 2003-02-25 2004-02-24 Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k

Country Status (20)

Country Link
US (3) US7825130B2 (es)
EP (1) EP1599205B1 (es)
JP (3) JP4590397B2 (es)
KR (1) KR101031163B1 (es)
CN (2) CN1780623B (es)
AR (1) AR043379A1 (es)
AT (1) ATE345800T1 (es)
AU (1) AU2004216340B9 (es)
BR (1) BRPI0407832A (es)
CA (1) CA2515590C (es)
CY (1) CY1106294T1 (es)
DE (1) DE602004003348T2 (es)
DK (1) DK1599205T3 (es)
ES (1) ES2276282T3 (es)
HK (2) HK1148225A1 (es)
MX (1) MXPA05008996A (es)
MY (1) MY136863A (es)
PT (1) PT1599205E (es)
TW (1) TWI323660B (es)
WO (1) WO2004075897A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
TWI423802B (zh) * 2007-05-22 2014-01-21 Otsuka Pharma Co Ltd 用於治療阿茲海默症之藥劑
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
JP5560203B2 (ja) 2008-01-17 2014-07-23 クイ・リウ 卵胞のインビトロ成熟方法
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
WO2009117387A2 (en) * 2008-03-17 2009-09-24 The Trustees Of Columbia University In The City Of New York Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
DK2502623T3 (en) 2008-06-06 2016-07-04 Children's Medical Center Corp Promoting axonregeneration the adult cns by management of protein translation
CA2777628C (en) * 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
JP5715303B2 (ja) * 2012-06-15 2015-05-07 公益財団法人先端医療振興財団 軽度認知障害の予防および／または治療剤
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
US20190142820A1 (en) * 2016-05-19 2019-05-16 National Cerebral And Cardiovascular Center Drug for preventing and/or treating dementia
JPWO2021230131A1 (es) * 2020-05-11 2021-11-18

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
AU5715994A (en) * 1992-12-24 1994-07-19 Otsuka Pharmaceutical Co., Ltd. Psoriasis remedy
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
AU3780699A (en) * 1998-05-01 1999-11-23 Rt Alamo Ventures, Inc. The treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
PT1599205E (pt) 2007-01-31
KR20050098960A (ko) 2005-10-12
US8329731B2 (en) 2012-12-11
US20100113515A1 (en) 2010-05-06
MY136863A (en) 2008-11-28
JP5208172B2 (ja) 2013-06-12
DE602004003348T2 (de) 2007-05-31
HK1148225A1 (zh) 2011-09-02
CN101829116A (zh) 2010-09-15
AU2004216340A1 (en) 2004-09-10
CN1780623A (zh) 2006-05-31
JP5566482B2 (ja) 2014-08-06
TWI323660B (en) 2010-04-21
EP1599205A1 (en) 2005-11-30
AU2004216340B9 (en) 2008-09-18
JP4590397B2 (ja) 2010-12-01
CA2515590C (en) 2011-09-13
HK1091409A1 (en) 2007-01-19
KR101031163B1 (ko) 2011-04-27
JP2006518732A (ja) 2006-08-17
US20060154963A1 (en) 2006-07-13
CY1106294T1 (el) 2011-10-12
CA2515590A1 (en) 2004-09-10
JP2010285456A (ja) 2010-12-24
US20130065921A1 (en) 2013-03-14
JP2013082735A (ja) 2013-05-09
CN1780623B (zh) 2011-09-14
WO2004075897A1 (en) 2004-09-10
DE602004003348D1 (de) 2007-01-04
CN101829116B (zh) 2015-11-25
AU2004216340B2 (en) 2008-07-31
TW200501954A (en) 2005-01-16
US8653104B2 (en) 2014-02-18
ES2276282T3 (es) 2007-06-16
US7825130B2 (en) 2010-11-02
EP1599205B1 (en) 2006-11-22
MXPA05008996A (es) 2005-10-18
BRPI0407832A (pt) 2006-02-14
DK1599205T3 (da) 2007-03-26
ATE345800T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
AR043379A1 (es) Compuestos de tetrazolilalcoxidihidrocarboestirilo como inhibidores del pten o abridores de canales maxi-k
JP7041166B2 (ja) トリアリールポリアミンを含む組成物および方法
SG159388A1 (en) Antibacterial agents
RU2010123052A (ru) Авенантрамидсодержащие композиции
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
CL2009000696A1 (es) Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras.
CL2009000695A1 (es) Compuestos derivados de 6-fenil-imidazo[1,2-a]piridina sustituidos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; utiles para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, de traumatismos cerebrales y de la epilepsia, entre otras.
NZ595448A (en) Hydroxythienoquinolones and related compounds as anti-infective agents
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
EP3197475B1 (en) Compositions useful for the prevention and/or treatment of infections and inflammations
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GT200600160A (es) Tratamiento del dolor
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
US10441588B2 (en) Methods and compositions for treating bacterial infection
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва
CL2008003895A1 (es) Compuestos derivados de 5-o-sustituido 3-n-fenil-1,3,4-oxadiazolonas, composicion farmaceutica, proceso de preparacion, y su uso para el tratamiento de un trastorno influenciado positivamente por la inhibicion de faah tal como trastornos alimenticios y patologias neurologicas y psiquiatricas, entre otras.
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos
AU2014301961B2 (en) Antimicrobial compositions and methods of use
RU2009114033A (ru) Средство и способ лечения эндометрита у коров
TH77903B (th) ตัวยับยั้ง pten หรือแมกซี-k แชนแนล โอเพนเนอร์
RU2306923C1 (ru) Способ лечения отодектоза у кошек

Legal Events

Date Code Title Description
FB Suspension of granting procedure